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the overall diagnostic accuracy from these tests. METHODS: We conducted a 
systematic review in five different electronic databases: Pubmed, Embase, The 
Cochrane Library, Database of Abstracts of Reviews of Effect (DARE) and Lilacs. 
We included both case control and consecutive enrollment studies that evalu-
ated the performance of the immunoassays in patients with suspected NMO in 
comparison with the 2006 Wingerchuk diagnostic criteria. Articles were assessed 
by two different reviewers, who also extracted data. RESULTS: 29 studies for three 
different immunoassays were included in the meta-analysis. To obtain a sum-
mary estimate for the sensitivity and specificity with 95% confidence interval 
a bivariate random effect model was used. The approximated sensitivity for the 
cell based assay, the tissue based assay and the ELISA test were 0.77(CI 95% 0.68-
0.84), 0.63(CI 95% 0.54-0.72) and 0.62(CI 95% 0.52-0.72), respectively. The mean 
specificity of the cell based assay was 0.99 (CI 95% 0.98-0.99), tissue based assay 
0.99 (CI 95% 0.97-0.99) and Elisa test 0.97(CI 95% 0.95-0.99). CONCLUSIONS: AQP4 
detection in serum with immunoassay is a great tool for the diagnosis of patients 
with NMO, due to the high specificity, allowing the clinician to differentiate this 
disease from other neurological conditions that resemble NMO. Due to differences 
in test effectiveness, cost-minimization studies would not be appropriate. Since 
the cost of immunoassays differs, these results will be useful in cost-effectiveness 
models.
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OBJECTIVES: Lipodystrophy syndromes (LD-S) are serious medical conditions char-
acterized by selective absence of the body’s adipose tissue, typically associated with 
insulin resistance, diabetes, dyslipidemia and other systemic diseases. Prevalence 
and natural history data on LD-S are sparse, derived primarily from anecdotal phy-
sician experience and case reports. This study explored the usefulness of EMRs for 
evaluating prevalence, natural history and disease burden of LD-S. METHODS: A 
unique retrospective cohort study of real-world EMR data along with expert review 
of text strings available in physician notes was conducted to classify and compare 
patients with an ICD-9-CM indication of LD-S (ICD-9-CM code 272.6), by type (con-
genital or acquired, generalized or partial, localized, or unable to classify). Data were 
captured from a large national network of US providers from 2000-2014, and limited 
to patients with no evidence of HIV. RESULTS: 1,637 patients with an ICD-9-CM 
diagnosis indicating LD-S and no evidence of HIV were identified. Upon detailed 
review of physician notes, 49 patients (3%) were classified as congenital general-
ized or partial LD, 227 (14%) as localized LD, and the remainder (83%) were unable 
to be classified due to non-specific physician notes. Among these subgroups, 71%, 
24% and 23% had high triglycerides (> 200 mg/dL); 69%, 30%, and 26% had Type 2 
diabetes; and 8%, 30%, and 12% had Type 1 diabetes, respectively. In the localized and 
unclassified groups, treatment by dermatologists and plastic surgeons was more 
common (18-30% versus 0%), and patients were more likely obese (18-21% versus 
16%). CONCLUSIONS: Over 80% of patients with an ICD-9-CM diagnosis indicating 
LD-S could not be classified due to non-specificity of coding. Given the current lack 
of standardization of the diagnostic code, it will be difficult to understand the true 
prevalence and natural history of LD-S utilizing EMR without an effort to standardize 
coding and documentation of LD-S.
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OBJECTIVES: Migraine-associated symptoms—nausea, photophobia and/or pho-
nophobia—can contribute to disability and direct healthcare costs. The com-
posite efficacy endpoint, total migraine freedom (TMF), is more rigorous than 
other pain endpoints and assesses pain freedom and absence of migraine-asso-
ciated symptoms, providing a more comprehensive understanding of treatment 
impact than evaluation of items individually. TMF was assessed for AVP-825, 
an investigational Breath Powered intranasal delivery system containing 22mg 
sumatriptan powder, vs 100mg oral sumatriptan (oral-SUM) in the COMPASS study 
(NCT01667679). METHODS: Multicenter, double-dummy, crossover, multi-attack 
study with two 12-week double-blind periods. Patients (2–8 attacks/month) were 
randomized to AVP-825 plus oral placebo or an identical placebo delivery system 
plus 100mg oral-SUM (period-1); treatment switched for period-2. Patients treated ≤ 5 
qualifying migraines/period (< 1 hour from onset, even if mild). Percentage of attacks 
with TMF (pain freedom and absence of migraine-associated symptoms, including 
vomiting) at timepoints from 10 minutes–2 hours post-dose was calculated post 
hoc and analyzed by chi-square test. RESULTS: 185 patients treated migraines in 
both periods, yielding 1531 migraines assessed (765 AVP-825, 766 oral-SUM). The 
percentage of attacks with TMF was significantly greater with AVP-825 vs oral-
SUM at all timepoints from 15–90 minutes: 15 minutes (7.2% vs 3.7%; P< .01), 30 
minutes (18.0% vs 10.8%; P< .001), 45 minutes (30.7% vs 21.4%; P< .001), 60 minutes 
(40.9% vs 33.3%; P< .01), 90 minutes (52.7% vs 45.6%; P< .01). At 2 hours, TMF rates did 
not differ significantly between treatments (60.6% for AVP-825 vs 56.7% oral-SUM; 
P= .11). CONCLUSIONS: AVP-825 (22mg sumatriptan) treatment of acute migraine 
results in higher rates of TMF at earlier timepoints than the most efficacious dose 
(100mg) of oral-SUM, despite delivering much less drug. These results demonstrate 
the superiority of AVP-825 using the most rigorous efficacy endpoint in migraine 
and are consistent with the other outcomes of COMPASS, indicating AVP-825 has 
superior early efficacy compared to oral-SUM.
est VPA concentrations were also higher when concomitant administrated of 
Biapenem compared to Meropenem . The rate of seizures in Biapenem group 
and Meropenem group were 29.73% and 35.42% respectively(P= 0.749). Most 
physicians discontinued the carbapenems, increased the VPA dose or added 
other antiepileptic drugs. CONCLUSIONS: The extent of decrease in VPA serum 
concentrations was greater in meropenem-treated patients than in biapenem-
treated cases. But Biapenem also decreased the VPA blood level as 70% and 
increased the risk of seizures , concomitant using of these medications should be 
avoided.
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OBJECTIVES: Chronic cluster headache (CCH) is a type of headache where attacks 
occur for more than a year without remission. The objective of this study was to 
identify evidence (a) on the disease and comorbidities burden (epidemiological, 
economic, humanistic) and (b) on the economic burden, complications and effi-
cacy of treatments recommended by the European Federation of the Neurological 
Societies (EFNS) guidelines. METHODS: Medline, Embase, Cochrane Library and 
NHS EED were searched using a predefined search strategy and selection criteria to 
retrieve publications on CCH in English language from 2000 onwards. RESULTS: In 
total, 10 studies were retrieved reporting data on disease burden and comorbidities 
of CCH. Of them, four reported humanistic burden, three reported comorbidities, 
two epidemiological outcomes and one study published economic data. Seven 
studies reported male-to-female ratio ranging from 3.0:1 to 4.65:1. Patient char-
acteristics were variable and inconsistent across studies. Four studies reported 
data on humanistic burden identified as depression, long-term disability, work 
loss and decreased ability to participate in social, family and housework activities. 
Economic burden was reported as number of visits to neurologists and neurosur-
geons and length of hospital stay. Five studies reported data on efficacy and safety 
of EFNS recommended CCH treatments, of which 3 were randomized controlled 
trials. Three studies reported overall response rates (ranging from 16-36%); two 
reported need for rescue medications (28-39%), pain-free at 30 minutes (37-47%) 
and headache relief at 30 minutes (47-52%). Two studies reported safety outcomes: 
zero adverse events and zero serious adverse events. No data on the economic 
burden of EFNS recommended treatments were identified. CONCLUSIONS: This 
review shows a large evidence gap regarding the disease burden, efficacy and 
safety of recommended treatments in CCH patients. The considerable impact of 
the economic, humanistic burden and comorbidities of CCH is indisputable for 
both the patient and the society.
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OBJECTIVES: Despite well-known benefits of pharmacotherapy to treat Parkinson 
disease (PD), conventional interventions may increase an individual’s risk of 
severe and sometimes life-threatening adverse outcomes. Our primary objective 
was to examine the risk of cardiovascular events, including acute myocardial 
infarction, heart failure, hypotension, and valvulopathy, among hospitalized 
individuals who received pharmacotherapy for PD. We hypothesized that indi-
viduals treated with non-ergot dopamine agonists (DAs) would be more likely to 
be diagnosed with cardiovascular events. We also examined the risk of cerebro-
vascular events (cerebrovascular accident and ischemic stroke) and the risk of 
adverse events among non-ergot DA only users. METHODS: Retrospective study 
of 14,122 inpatients identified from the Cerner Health Facts® database between 
January 1, 2000 and December 31, 2012 who received pharmacological treat-
ment for PD. Controls were matched to cases on age, race, and sex. Multivariable 
logistic regressions were used to estimate associations between non-ergot DA 
exposure and the risk of adverse events. Risk estimates were calculated as odd 
ratios (OR) with 95% confidence intervals (CI). RESULTS: Inpatients were primarily 
Caucasian (91.2%), men (54.0%), and 80 years of age or older (47.4%) at admission. 
The majority of patients were levodopa users (87.2%) and antiparkinson mono-
therapy was common (71.7%). Relative to levodopa monotherapy, an increased risk 
of heart failure was observed with non-ergot DA (OR 1.22, CI 1.02-1.50, p = 0.04) 
and pramipexole monotherapy (OR 1.29, CI 1.00-1.66, p = 0.05). No risk of other 
cardiovascular events or cerebrovascular events was identified. CONCLUSIONS: 
Treating PD provides substantial benefits to function, mobility, and survival. It is 
important to treat PD; therefore, knowledge of cardiovascular and cerebrovascu-
lar risks associated with pharmacotherapies is essential to informing treatment 
decisions.
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OBJECTIVES: Antibodies against water channel protein aquaporin 4 (AQP4) in 
astrocytes play a role in the etiology and physiopathology of neuromyelitis optica 
(NMO); detection of this immunoglobulin in serum is highly suggestive of this 
diagnosis. There are several immunoassays to detect the antibody with differ-
ent sensitivities and specificities. We conducted a meta-analysis to determine 
